Always good those briefings although the questions asked are bit weak and not very searching
Have you gone back and listened to all the previous ones?
Printable View
I would take that last sentence with a grain of salt --Otherwise why all the fuss and expense of the KP trials in the USA? (when THEY are sorted things should be looking up--just that things take so loooooong.
I dont subscribe to the ''company is going down the tubes'' theory --but those days of ''better get in now before the SP goes ballistic'' are over for the medium term at least (unless something big happens in the mean time)
I would expect we will get some serious PR stuff before the June 7 cut off--They need to get that SP up
Whenever I hear DD going on about that e-commerce site, like it's some amazing new technology allowing people to order something online, it makes me lose confidence. Have you actually seen it? It's just a simple form on their website. There is nothing innovative or exciting here. How many people are going to order a kit instead of going to see their doctor first? Almost non IMO. Just more hype.
Looking at the price relative to the rights issue 62c seems to be fair value to me and in respects to the pre-announcement price represents a discount of a small margin. I recall a similar reaction to the last rights issue followed by a healthy bounce. Wouldn't be surprised if we see something like that this time around, if a little more subdued.
As funny as it seems I suspect the market for hypochondriacs and the self diagnosing is probably reasonably large. Not enough to bank roll these guys but maybe a dollar in it. Can't imagine its a great way to endear yourself to the medical profession either.
That said - seems like they have no real distribution plan. Always concerns me when a company needs to set up its own sales force as they can't find a distributor. Next thing happens is they can't wholesale it so end up retail or going direct.. slippery slope. They are opening new markets (Sth East Asia) without positive cash flow from existing markets - is that really a risk they need to take - or can afford to take?
Singapore is a market opportunity only recognised relatively recently but one they obviously feel is worth pursuing in addition to everything else they are working on. The funds from the CR will enable this risk to be taken as well as continuing the push into the US.
Like the PEB management team, I hope both markets prove to be highly successful.